Aripiprazole In the Treatment of Irritability Associated with Autistic Disorder in Pediatric Patients
Aripiprazole In the Treatment of Irritability Associated with Autistic Disorder in Pediatric Patients
复制标题
DOI：
10.2165/11207230-000000000-00000
复制
发表时间：
2011-01-01
期刊：
影响因子：
3.7
通讯作者：
Curran, Monique P.
中科院分区：
文献类型：
--
作者：
Curran, Monique P.
阿立哌唑是一种非典型抗精神病药，获批用于治疗6- 17岁儿童孤独症相关易激惹，在两项6-17岁儿童孤独症相关易激惹的随机、双盲、安慰剂对照研究中，与安慰剂相比，阿立哌唑2-15 mg/天治疗8周，导致终点时异常行为检查表易怒子量表评分显著改善在两项8周研究和一项52周研究中，阿立哌唑在该患者群体中通常耐受良好，大多数不良事件的严重程度为轻度至中度。在短期和长期研究中，阿立哌唑均与体重增加相关;长期研究的数据表明，体重增加在3-6个月时达到平台期。
Aripiprazole is an atypical antipsychotic approved for the treatment of irritability associated with autistic disorder in pediatric patients aged 6-17 years.In two, randomized, double-blind, placebo-controlled studies in pediatric patients aged 6-17 years with irritability associated with autistic disorder, 8 weeks of treatment with aripiprazole 2-15 mg/day, compared with placebo, resulted in significant improvements in the Aberrant Behavior Checklist Irritability sub-scale score at endpoint (primary endpoint), and the mean Clinical Global Impression-Improvement score.Aripiprazole was generally well tolerated in this patient population in the two 8-week studies and a 52-week study, with most adverse events being mild to moderate in severity. Aripiprazole was associated with weight gain in both the short- and long-term studies; data from the long-term study indicated that the increase in bodyweight reached a plateau at 3-6 months.